Frequency reports Q1 net loss $19.5M; cash $66.7M, debt prepaid; MS program on track for 2024

Korro Bio, Inc.

2024-Q1 EPS reported -$72.20

Net loss of $19.5M vs $23.4M in Q1 2022; R&D expenses $11.4M, G&A $9.2M.
Cash, equivalents and marketable securities $66.7M at March 31, 2023; all outstanding loans prepaid in April.
MS remyelination program on track for clinical start in H1 2024; novel NCEs show robust in vivo remyelination.
Preclinical data show statistical improvements in MRI white matter volume and oligodendrocyte differentiation across species.
Company exploring strategic options to create shareholder value; restructuring extends cash runway into 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Korro Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $19.5 million.

Period: the quarter ended March 31, 2023
Net income: Net loss was $19.5 million
Result: reported results

Exact text from the filing

On May 12, 2023, Frequency Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023

View on SEC.gov

2 earnings releases filed in the last 30 days. Browse all earnings releases →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.